Citigroup’s Coherus Oncology CHRS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q4
– Sell
-500
Closed -$8K – 7679
2018
Q3
$8K Sell
500
-500
-50% -$8.86K ﹤0.01% 7400
2018
Q2
$14K Sell
1,000
-300
-23% -$4.29K ﹤0.01% 7067
2018
Q1
$14K Sell
1,300
-1,100
-46% -$12K ﹤0.01% 6907
2017
Q4
$21K Buy
2,400
+200
+9% +$2.14K ﹤0.01% 6702
2017
Q3
$29K Sell
2,200
-2,900
-57% -$38.4K ﹤0.01% 6269
2017
Q2
$73K Buy
5,100
+4,200
+467% +$80.8K ﹤0.01% 5553
2017
Q1
$19K Buy
900
+300
+50% +$7.38K ﹤0.01% 6274
2016
Q4
$17K Buy
+600
New +$16.8K ﹤0.01% 6584

Other funds holding CHRS

Citigroup's CHRS Position: Q3 2026 in Review

Citigroup increased its Coherus Oncology (CHRS) stake by 140% in Q3 2026, buying an estimated $123K and bringing the position to 154,112 shares worth $186K. The position accounts for ﹤0.01% of the portfolio, ranked #4231.

Citigroup first reported a position in CHRS in Q4 2014 and has held it in 48 quarters since. The position peaked at $12.7M in Q4 2021. 135 funds tracked by Wall St. Rank hold CHRS as of Q3 2026.

  • Citigroup held 154,112 shares of Coherus Oncology worth $186K as of Q3 2026.
  • Citigroup bought 89,770 Coherus Oncology shares in Q3 2026, an estimated $123K.
  • Coherus Oncology made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #4231 holding.
  • Citigroup first reported a position in Coherus Oncology in Q4 2014 and has held it in 48 quarters since.
  • Citigroup's Coherus Oncology position peaked at $12.7M in Q4 2021.
  • 135 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.